The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a potential one-and-done treatment for alpha-1 antitrypsin deficiency.

Chaudhary Sarwan Kumar Himachal Pradesh Krishi Vishvavidyalaya, Palampur, successfully concluded a two-day workshop on ...

Regeneron teams up with Tessera to advance TSRA-196, aiming to correct the genetic cause of AATD as preclinical data support its move toward trials.

More than half of Canadian households have at least one pet. Humans are eager to deepen their connection with animals but the current science of cloning and decoding animal communication doesn't bring ...